Amarantus Appoints Russell Miller as Director of Investor Relations
SUNNYVALE, Calif.-- Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a
biotechnology company discovering and developing treatments and diagnostics for
diseases associated with the neurodegeneration and apoptosis, today announced it has
appointed Russell Miller as Director of Investor Relations.
Mr. Miller previously served as Director of Investor Relations for US Data Works and for
Force Protection, Inc. He has assisted in raising capital for companies both public and
private, including real estate financing, development, and joint ventures for over 20 years.
He has successfully participated in private placements, mezzanine financing, joint
ventures, mergers and acquisitions, reverse mergers, national exchange up-listings and
acquisitions for companies on the OTC, AMEX, and NASDAQ. As a consultant Mr. Miller
has assisted a multitude of companies by developing their strategic plans for growth,
liquidity, and return on equity by facilitating relationships with investment bankers,
government relations officers, financiers, the media, and marketing and public relation
firms. He has a broad range of worldwide contacts throughout the investment banking
community, which include a large number of accredited investors and investment